Phaseline

Companies › Jazz Pharmaceuticals

Jazz Pharmaceuticals: clinical trials, targets and expected readouts

11 active drug programs in 39 registered trials: 18 Phase 2, 14 Phase 1, 6 Phase 3, 1 Phase 4; Oncology, Neurology, Other, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cannabidiol (GWP42003)
Cannabinoid CB1 receptor negative allosteric modulator
CNR1Phase 4Lennox Gastaut Syndrome; Focal SeizuresAug 2027
Zanidatamab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Gastric Neoplasms; Metastatic HER2-positive Breast Cancer; Biliary Tract Cancer; Breast Cancer …Dec 2026
Xywav
calcium, magnesium, potassium, and sodium oxybates solution
–Phase 3NarcolepsyDec 2027
Dordaviprone (ONC201)
Imipridone; selective antagonist of dopamine receptors and trace amine-associated receptor
–Phase 3H3 K27MJun 2028
JZP3507 (ONC206)
DRD2 agonist
DRD2Phase 2Meningioma; Advanced Pheochromocytoma and Paraganglioma; Central Nervous System NeoplasmsMar 2027
Lurbinectedin–Phase 2Extensive-stage Small-cell Lung Cancer; Refractory Ewing Sarcoma; Extensive-Stage Small Cell Lung Cancer; Lung Cancer …Jan 2028
JZP926 capsule–Phase 2Juvenile Myoclonic EpilepsyAug 2028
JZP047–Phase 1Healthy ParticipantsNov 2026
JZP269–Phase 1Healthy ParticipantsFeb 2027
JZP898–Phase 1Advanced Solid TumorNov 2027
JZP815
MAPK pathway inhibitor
–Phase 1Advanced CancerApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07377539JZP047Phase 1Healthy ParticipantsOtherNov 2026
NCT06497530LurbinectedinPhase 2Extensive-Stage Small Cell Lung CancerOncologyDec 2026
NCT05099666LurbinectedinPhase 1Advanced Soft-tissue SarcomaOncologyDec 2026
NCT05578326LurbinectedinPhase 2Lung CancerOncologyDec 2026
NCT06695845ZanidatamabPhase 2Breast CancerOncologyDec 2026
NCT06043427ZanidatamabPhase 2Gastroesophageal AdenocarcinomaOncologyDec 2026
NCT05636111LurbinectedinPhase 1Ovarian CancerOncologyDec 2026
NCT07813663JZP269Phase 1Healthy ParticipantsOtherFeb 2027
NCT04541082JZP3507 (ONC206)Phase 1Central Nervous System NeoplasmsOncologyMar 2027
NCT05615818ZanidatamabPhase 3Biliary Tract NeoplasmsOncologyJun 2027
NCT05244239LurbinectedinPhase 1Extensive Stage Lung Small Cell CarcinomaOncologyJul 2027
NCT05044819Cannabidiol (GWP42003)Phase 4Lennox Gastaut SyndromeGastroenterologyAug 2027
NCT06228066LurbinectedinPhase 2Small Cell Carcinoma of the BladderOncologySep 2027
NCT05152147ZanidatamabPhase 3Gastric NeoplasmsOncologySep 2027
NCT07233239Cannabidiol (GWP42003)Phase 1Focal SeizuresNeurologyNov 2027
NCT06108050JZP898Phase 1Advanced Solid TumorOncologyNov 2027
NCT04802174LurbinectedinPhase 1SCLCOncologyDec 2027
NCT07296705ZanidatamabPhase 2Muscle Invasive Bladder Cancer (MIBC)OncologyDec 2027
NCT07625280XywavPhase 3NarcolepsyNeurologyDec 2027
NCT07102381ZanidatamabPhase 2HER2-positive Breast CancerOncologyDec 2027
NCT05734066LurbinectedinPhase 1Refractory Ewing SarcomaOncologyJan 2028
NCT07192068ZanidatamabPhase 2Non-Small Cell Lung CancerOncologyMar 2028
NCT05557045JZP815Phase 1Advanced CancerOncologyApr 2028
NCT06435429ZanidatamabPhase 3Metastatic HER2-positive Breast CancerOncologyApr 2028
NCT07290985ZanidatamabPhase 2Gastroesophageal AdenocarcinomaOncologyJun 2028
NCT05580562Dordaviprone (ONC201)Phase 3H3 K27MOncologyJun 2028
NCT05918640LurbinectedinPhase 1Ewing SarcomaOncologyJul 2028
NCT07723963JZP926 capsulePhase 2Juvenile Myoclonic EpilepsyNeurologyAug 2028
NCT07533942JZP3507 (ONC206)Phase 2MeningiomaOncologyOct 2028
NCT06282575ZanidatamabPhase 3Biliary Tract CancerOncologyDec 2028
NCT07282587JZP3507 (ONC206)Phase 2Advanced Pheochromocytoma and ParagangliomaOncologyDec 2028
NCT07405476ZanidatamabPhase 2Colon CarcinomaOncologyDec 2028
NCT05035836ZanidatamabPhase 2Breast CancerOncologyDec 2028
NCT07176312ZanidatamabPhase 2Gastroesophageal AdenocarcinomaOncologyMar 2029
NCT07153055LurbinectedinPhase 1Small Cell Lung Cancer ( SCLC )OncologyApr 2029
NCT07459634LurbinectedinPhase 2Extensive-stage Small-cell Lung CancerOncologyAug 2029
NCT04607954LurbinectedinPhase 2Platinum-Resistant Lung Small Cell CarcinomaOncologySep 2030
NCT07328425LurbinectedinPhase 2Desmoplastic Small Round Cell TumorOncologyOct 2030
NCT05868226ZanidatamabPhase 1HER2-positive Breast CancerOncologyDec 2030

From the company's SEC filings

Cash and short-term investments of $2.9bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CNR1 (1) DRD2 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Corcept Therapeutics DualityBio Exelixis Incyte Hutchmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.